Quinolinone PDE2 Inhibitors for Schizophrenia
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antipsychotic treatments for schizophrenia are inadequate due to low efficacy and severe side effects, leading to high medication noncompliance, and there is a need for therapies that can effectively target the underlying neurological pathways involving phosphodiesterase (PDE) enzymes.
Innovation Solution
Development of quinolinone compounds that act as selective inhibitors of the PDE2 enzyme, which are designed to increase levels of cyclic nucleotides such as cAMP and cGMP in the brain, thereby addressing the pathogenesis of schizophrenia and related disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current antipsychotic treatments (typical or atypical) are used, then psychotic symptoms may be suppressed, but severe side effects occur including metabolic, extrapyramidal, prolactic and cardiac adverse events
Solution Approach 1:
The patent changes the pharmacological parameter by targeting a different enzyme (PDE2) compared to conventional antipsychotics. The quinolinone compounds selectively inhibit PDE2, altering the biochemical pathway to increase cAMP and cGMP levels without affecting dopamine receptors, thereby achieving therapeutic effects through a different mechanism that avoids traditional side effects
Solution Approach 2:
The patent uses cyclic nucleotides (cAMP and cGMP) as intermediary molecules to transmit the therapeutic effect. By inhibiting PDE2, the compounds increase levels of these second messengers, which then mediate the downstream effects on neuronal function and gene expression, providing a indirect pathway to treat schizophrenia symptoms without direct dopamine receptor interaction
2Reliability
If current antipsychotic treatments are used, then some symptom relief may be achieved, but medication noncompliance rate is extremely high due to intolerance and unacceptable side effects
Solution Approach 1:
The patent converts the previously harmful over-inhibition of PDE2 (which leads to cognitive deficits and negative symptoms) into a beneficial therapeutic effect. By selectively inhibiting PDE2 with quinolinone compounds, the treatment restores normal cAMP/cGMP signaling, improving cognitive function and reducing negative symptoms without the side effects that cause noncompliance
3Quantity of substance
If PDE2 activity is increased, then cAMP and cGMP levels decrease leading to cognitive impairment and negative symptoms, but PDE2 inhibition may cause off-target effects on other PDE isoforms
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular features that confer selectivity for PDE2 over other PDE isoforms. The quinolinone core structure combined with specific substituents creates a molecule that fits the PDE2 active site geometry and chemistry, allowing selective inhibition without affecting other PDE families
Solution Approach 2:
The patent segments the PDE enzyme family into distinct targets by exploiting the unique structural features of PDE2. The compounds are designed to interact specifically with PDE2's catalytic domain and regulatory features, separating PDE2 inhibition from other PDE activities through selective molecular recognition
Data Source
AI summary
The present invention is directed to quinolinone compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.